Two views on suicide risk with antidepressants

September 23, 2004

CINCINNATI, September 2004 - The recent FDA proposal to force antidepressants to carry warnings about increased suicide risk is the subject of a pair of articles by leading experts in The Annals of Pharmacotherapy. According to "Antidepressants, Suicide, and the FDA: A Loose Association," the FDA proposal is premature and may be counterproductive. The companion piece "Antidepressants: an Avoidable and Solvable Controversy" cautions the warnings simply don't address the fundamental problem. Both articles are posted at The Annals of Pharmacotherapy's Articles Ahead of Print (www.theannals.com) and will appear in the journal's October issue.

In "Antidepressants, Suicide, and the FDA: A Loose Association," author Patrick R Finley PharmD, Professor of Clinical Pharmacy, Psychopharmacology and Behavioral Health at the University of California at San Francisco, notes that although the FDA warning appears reasonable, it has generated considerable controversy. Perhaps most notably, the warning may discourage depressed patients from seeking appropriate medical care.

Based on thousands of patients evaluated over the years, many experts see no conclusive evidence that selective serotonin reuptake inhibitors (SSRIs), the antidepressants in question, increase suicide risk in adults. Instead, trends have actually shown a decrease in numbers of suicides over the years that SSRI use has grown. However, caution should be used when interpreting these data, Finley notes. In particular, antidepressant studies in children and adolescents are much more limited, with more studies needed even to show conclusively that SSRIs work in kids.

Ultimately, improvements in clinical trial designs for SSRIs and other psychotropic medications may clarify any suicide risk. Possible strategies include better tests to identify suicidal tendencies, more variety in patient selection, and improved postmarketing surveillance. Until then, it's important to remind patients that untreated depression carries a much higher suicide risk than any antidepressant medication.

The article series continues with "Antidepressants: an Avoidable and Solvable Controversy," by Jay S. Cohen, M.D., Associate Professor (voluntary) of Family and Preventive Medicine and of Psychiatry at the University of California, San Diego. Dr. Cohen highlights how poor FDA and drug industry procedures often lead to the approval and prescribing of drug doses that are too strong for many patients. As a result, many suffer unnecessarily from dose-related side effects.

In the case of antidepressants, mild depression is often treated with doses studied for major depression. Typically, study results are averaged and information on the wide range of individual patient responses is ignored, according to Cohen. Also, studies often lack elderly subjects, obese or underweight patients, and those taking other medications that might interfere with antidepressants. In addition, usually no accommodation is made for patients with long histories of medication reactions or sensitivities. Cohen states, "All of these factors lead to a lack of precision in how antidepressants are prescribed to individuals." The article cites others who have mirrored these findings as well.

Cohen calls on both the drug industry and FDA to provide better dose-response research. This includes full disclosure about all doses found superior to placebo in clinical trials. Additionally, he asks for better guidelines on treating the various depressive disorders and individualizing treatment based on individual patient needs and tolerances.

Ultimately, new warnings may improve awareness about risks, but more is needed to reinforce patient trust while improving prescriber skill and confidence. To ensure the greatest level of patient safety and maximize treatment effectiveness, practical dosing strategies that minimize risks with antidepressants are required.
-end-
The Annals of Pharmacotherapy is a leading peer-reviewed, international pharmacotherapy journal for physicians, pharmacists, and other healthcare practitioners. Published by Harvey Whitney Books Company, for over 38 years The Annals has featured articles directly related to the safe, effective, and economical use of medications and related devices in patient care. The journal's editorial office is headquartered at 8044 Montgomery Road, Suite 415, Cincinnati, Ohio 45236-2998, USA. The journal is available in print and online in full text at www.theannals.com.

Annals of Pharmacotherapy

Related Suicide Articles from Brightsurf:

Suicide prevention in COVID-19 era
COVID-19 presents a new and urgent opportunity to focus political will, federal investments, and global community on the vital imperative of suicide prevention.

Racial discrimination linked to suicide
New research findings from the University of Houston indicate that racial discrimination is so painful that it is linked to the ability to die by suicide, a presumed prerequisite for being able to take one's own life, and certain mental health tools - like reframing an incident - can help.

Factors associated with firearm suicide risk
Researchers compared the risk of suicide by firearm based on sociodemographic characteristics of US adults.

Suicide mortality and COVID-19
Reasons why U.S. suicide rates may rise in tandem with the coronavirus disease 2019 (COVID-19) pandemic are explained in this article that also describes opportunities to expand research and care.

Media reports of celebrity suicide linked to increased suicide rates
Media reporting of suicide, especially celebrity suicides, is associated with increases in suicide in the general population, particularly by the same method as used by the celebrity, finds an analysis of the latest evidence published by The BMJ today.

More youth suicide found in poor communities across US
A study led by Jennifer Hoffmann, M.D., from Ann & Robert H.

BU study finds new factors linked to suicide
A new study led by Boston University School of Public Health (BUSPH) researchers finds that physical illness and injury raises the risk of suicide in men but not women, along with a plethora of other insights into the complex factors that may increase a person's risk of suicide.

Investigating the full spectrum of suicide
A recent study published in Injury Prevention described a method for categorizing self-injury mortality (SIM) to help us better examine national trends for today's epidemics of suicide and drug-related deaths.

Between 16 and 18% of preadolescents have ideas of suicide
Thinking of taking one's own life (ideation), planning it, threatening to do it or even attempting to do it is regarded as suicidal behaviour.

Social networks and suicide prevention
Depression and mental health problems are increasing - and suicide and drug overdose rates are rising dramatically in the USA.

Read More: Suicide News and Suicide Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.